Show simple item record

dc.contributores-ES
dc.creatorCandia, Roberto; Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile.Unidad de Medicina Basada en Evidencia, Facultad de Medicina, Pontificia Universidad Católica de Chile.
dc.date2012-07-30
dc.date.accessioned2019-11-11T18:27:02Z
dc.date.available2019-11-11T18:27:02Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/2094
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110971
dc.descriptionBackground & Aims: Rebound acid hypersecretion (RAHS) has been demonstrated after 8 weeks of treatment with a proton-pump inhibitor (PPI). If RAHS induces acid-related symptoms, this might lead to PPI dependency and thus have important implications. Methods: A randomized, double-blind, placebo-controlled trial with 120 healthy volunteers was conducted. Participants were randomized to 12 weeks of placebo or 8 weeks of esomeprazole 40 mg/d followed by 4 weeks with placebo. The Gastrointestinal Symptom Rating Scale (GSRS) was filled out weekly. A score of >2 on 1 of the questions regarding heartburn, acid regurgitation, or dyspepsia was defined as a clinically relevant acid-related symptom. Results: There were no significant differences between groups in GSRS scores at baseline. GSRS scores for acid-related symptoms were significantly higher in the PPI group at week 10 (1.4 ± 1.4 vs 1.2 ± 0.9; P = .023), week 11 (1.4 ± 1.4 vs 1.2 ± 0.9; P = .009), and week 12 (1.3 ± 1.2 vs 1.0 ± 0.3; P = .001). Forty-four percent (26/59) of those randomized to PPI reported ?1 relevant, acid-related symptom in weeks 9–12 compared with 15% (9/59; P < .001) in the placebo group. The proportion reporting dyspepsia, heartburn, or acid regurgitation in the PPI group was 13 of 59 (22%) at week 10, 13 of 59 (22%) at week 11, and 12 of 58 (21%) at week 12. Corresponding figures in the placebo group were 7% at week 10 (P = .034), 5% at week 11 (P = .013), and 2% at week 12 (P = .001). Conclusions: PPI therapy for 8 weeks induces acid-related symptoms in healthy volunteers after withdrawal. This study indicates unrecognized aspects of PPI withdrawal and supports the hypothesis that RAHS has clinical implications.es-ES
dc.languagees
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2094/5711
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2094/5712
dc.sourceRevista Médica de Chile; Vol. 140, núm. 8 (2012): AGOSTO 2012es-ES
dc.source0034-9887
dc.subjectes-ES
dc.titleAnálisis crítico de un artículo La suspensión de inhibidores de la bomba de protones induciría síntomas de reflujo.es-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record